MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/biomedicines13092186

Медицинская библиотека · Biomedicines · 2025

Advanced Immunomodulation in Rheumatoid Arthritis: Immune Checkpoints, microRNAs, and Cell-Based Therapies.

Pascual-García Sandra, Cobo Raúl, Bolinches José Luis, Ortiz Iván, Viamonte Pedro, Sempere-Ortells José Miguel, Martínez-Peinado Pascual

СтатьяОбзорПеревод в очереди

Аннотация

Background/

Objectives

Rheumatoid arthritis (RA) is a chronic autoimmune disorder marked by persistent synovial inflammation, progressive joint destruction, and systemic complications. Despite significant progress in targeted therapies, major clinical challenges persist, including heterogeneous treatment responses and therapeutic resistance. This review aims to critically evaluate emerging immunomodulatory strategies-focusing on immune checkpoints, microRNAs (miRNAs), and cell-based therapies-as potential diagnostic and therapeutic tools.

Methods

This non-systematic literature review involved a comprehensive analysis of recent studies to investigate emerging immunomodulatory strategies in RA. Special attention was given to immune checkpoint pathways-cytotoxic T-lymphocyte antigen 4 (CTLA-4); programmed death-1 (PD-1) and its ligand, PD-L1; and inducible T-cell costimulator (ICOS)-as well as cell-based therapies. Additionally, miRNA-based interventions were examined for their diagnostic and therapeutic potential.

Results

Immune checkpoint modulation has demonstrated preclinical efficacy in attenuating inflammatory responses and restoring immune tolerance. Concurrently, miRNAs have emerged as both biomarkers and therapeutic agents, with exosome-based delivery systems enhancing their function. Cell-based therapies have shown robust immunoregulatory effects with acceptable safety profiles. Notably, integrative strategies that combine checkpoint inhibitors, cell-based interventions, and miRNA delivery exhibit synergistic effects and offer a promising avenue for personalised treatment, when guided by molecular and transcriptomic profiling. The majority of these approaches remain at the preclinical or early translational stage.

Conclusions

Targeted immunomodulation is poised to transform RA management. The integration of cell therapies, checkpoint inhibition, and miRNA manipulation with omics technologies holds promise for enhancing therapeutic precision and safety. Advancing towards personalised immunotherapy will necessitate a multidisciplinary and patient-centred effort.

Для цитирования: Pascual-García Sandra, Cobo Raúl, Bolinches José Luis, Ortiz Iván, Viamonte Pedro, Sempere-Ortells José Miguel, Martínez-Peinado Pascual. Advanced Immunomodulation in Rheumatoid Arthritis: Immune Checkpoints, microRNAs, and Cell-Based Therapies.. Biomedicines. 2025. DOI: 10.3390/biomedicines13092186.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.